Breast Cancer

Evolving role of ctDNA in breast cancer

With the advent of next-generation sequencing technologies, circulating tumor DNA (ctDNA) has now become an important player in the diagnosis,…

Date: 26th October 2022

Breast Cancer Sessions: Highlights from ESMO 2022 with Elisa Agostinetto & Evandro de Azambuja

The European Society for Medical Oncology (ESMO) Annual Meeting, showcased an array of updates in breast cancer care and management,…

Date: 10th October 2022

ESMO 2022: Updates in Breast Cancer

The European Society for Medical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data…

Date: 26th September 2022

iwCART Sessions: CAR-T clinical advances in breast and ovarian cancer

The International Workshop on CAR-T (iwCAR-T) 2022 featured many updates on the development of CAR-T therapies for the treatment of…

Date: 5th August 2022

Clinical Applications of ctDNA in Oncology

Circulating tumor DNA (ctDNA) are small fragments of nucleic acid that are released into the circulating system via multiple mechanisms…

Date: 29th July 2022

ASCO 2022: Updates in Breast Cancer

The American Society of Clinical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data…

Date: 1st July 2022

Updates in radiation oncology from ESTRO 2022

This year’s European Society for Radiotherapy and Oncology (ESTRO) annual congress took place in Copenhagen, Denmark, from 6-10 May 2022,…

Date: 27th May 2022

Breast Cancer Sessions: Treatment de-escalation in TNBC

The development of complex and effective therapies has improved outcomes in breast cancer, highlighting the need for strategies to escalate…

Date: 20th May 2022

Trial updates from ESMO Breast Cancer 2022: TUXEDO-1, monarchE, KEYNOTE-355

The European Society for Clinical Oncology (ESMO) Breast Cancer Conference was a hybrid event, held virtually and Berlin, Germany. This…

Date: 16th May 2022

Novel treatment approaches in HR+/HER2- breast cancer

Resistance to endocrine therapy in patients with hormone-receptor positive (HR+), HER2-negative breast cancer inevitably results in relapse and metastasis, leading…

Date: 25th March 2022

The Breast Cancer Sessions: Highlights from SABCS 2021

The San Antonio Breast Cancer Symposium (SABCS) 2021 saw ground-breaking data and developments in breast cancer being presented and in…

Date: 11th March 2022

Updates on HER2-positive breast cancer

HER2-positive breast cancer accounts for 15-20% of all breast cancer cases. It was associated with a poor prognosis until the…

Date: 15th February 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter